U.S. Stem Cell's competitors

U.S. Stem Cell's competitors include Endologix, CTD Holdings, Vital Therapies and Pfenex
Add company...
U.S. Stem Cell
U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage.
Endologix
Endologix is a developer and manufacturer of minimally invasive treatments for aortic disorders.
CTD Holdings
CTD Holdings, Inc., is a biotechnology company that develops cyclodextrin-based products for the treatment of diseases.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Pfenex
Pfenex is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins.
Founding Date
Founding Date
N/A
Founding Date
1992
Founding Date
1990
Founding Date
2003
Founding Date
2009
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Sunrise, US HQ
Locations
Irvine, US HQ
Rosmalen, NL
Locations
Alachua, US HQ
Locations
San Diego, US HQ
Locations
San Diego, US HQ
Employees
Employees
3
Employees
782
Employees
9
Employees
87
Employees
70 4% increase
Valuation ($)
Valuation ($)
9.7 m
Valuation ($)
360.7 m
Valuation ($)
35.6 m
Valuation ($)
212.1 m
Valuation ($)
81.2 m
Facebook followers
Facebook followers
1.3 k
Facebook followers
132
Facebook followers
60
Facebook followers
N/A
Facebook followers
5.7 k
Twitter followers
Twitter followers
1.7 k
Twitter followers
219
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
9.4 k

Financial

Revenue (est.)
Revenue (est.)
$3.1m (FY, 2016)
Revenue (est.)
$192.9m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$972k (FY, 2016)
Cost of goods
$69.1m (FY, 2016)
Cost of goods
$198.4k (FY, 2016)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$2.1m (FY, 2016)
Gross profit
$123.8m (FY, 2016)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($2.1m) (FY, 2016)
Net income
($154.7m) (FY, 2016)
Net income
($4.2m) (FY, 2016)
Net income
($41m) (FY, 2016)
Net income
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles